Regulatory Affairs in Clinical Research: A Beginner’s Guide

Every drug that reaches a patient has passed through an invisible but essential gateway. That gateway is regulatory affairs — and most students have never heard of the professionals who manage it, or how consequential their work truly is.

WHAT IS REGULATORY AFFAIRS: Regulatory Affairs (RA) is the function within pharmaceutical, biotechnology, and medical device organisations responsible for obtaining and maintaining the regulatory permissions needed to develop, manufacture, and market products across specific geographies and therapeutic indications.

In the clinical research context, RA professionals work at the intersection of science, law, and structured communication. Their mandate is to ensure that every formal interaction with a regulatory authority — the U.S. FDA, the European Medicines Agency (EMA), CDSCO, or other national bodies — is accurate, complete, timely, and fully compliant.

WHAT REGULATORY PROFESSIONALS DO ACROSS THE TRIAL LIFECYCLE: Before a trial begins, RA teams prepare and submit Investigational New Drug (IND) applications to the U.S. FDA, or the equivalent new drug permission applications to CDSCO under India’s New Drugs and Clinical Trials (NDCT) Rules 2019. In the European Union, they file applications under the EU Clinical Trials Regulation 536/2014, which became fully applicable on 31 January 2022. They coordinate Ethics Committee approvals and manage site-level regulatory documentation.

During the trial, RA professionals manage ongoing regulatory correspondence, prepare protocol amendment submissions, maintain the Trial Master File (TMF), and ensure continued compliance with the trial’s original regulatory authorisation.

After the trial, they contribute to the compilation of regulatory dossiers — structured, evidence-based packages formatted as Common Technical Documents (CTD/eCTD) — submitted to regulatory authorities in support of marketing approval applications.

THE SKILLS REQUIRED: Regulatory Affairs demands precision and breadth. Professionals must command drug development science, applicable regulatory guidelines (ICH, GxP, 21 CFR), recognised submission formats, and the specific documentation expectations of each target market. Written communication is equally critical — regulatory submissions and responses to authority queries must be both scientifically rigorous and strategically clear.

BUILDING A CAREER IN REGULATORY AFFAIRS: For pharmacy, medicine, and life science graduates, RA offers a structured, progressive career — from Regulatory Coordinator through to Manager, Director, and Vice-President of Regulatory Affairs. It is a discipline where expertise builds systematically and where deep experience carries genuine, lasting market value.

References

1. Central Drugs Standard Control Organisation (CDSCO). New Drugs and Clinical Trials Rules (NDCT Rules). Ministry of Health & Family Welfare, Government of India; 2019.
2. European Parliament and of the Council. Regulation (EU) No 536/2014 on Clinical Trials on Medicinal Products for Human Use. Official Journal of the European Union; 2014.
3. International Council for Harmonisation (ICH). ICH M4: Common Technical Document (CTD) for the Registration of Pharmaceuticals for Human Use. ICH; 2022.
4. Prasad K. Regulatory submissions in clinical research: An overview. Perspect Clin Res. 2017;8(2):65–70.